Xeljanz - direct healthcare professional communication (DHPC)

tofacitinib citrate

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Direct healthcare professional communication (DHPC): Xeljanz (tofacitinib): increased risk of major adverse cardiovascular events and malignancies with use of tofacitinib relative to TNF-alpha inhibitors

Key facts

• Medicine name:
  Xeljanz
• Active substance:
  tofacitinib citrate
• Therapeutic area (MeSH):
  Arthritis, Rheumatoid
• Procedure number:
  EMEA/H/C/004214
• Regulatory outcome:
  Variation
• DHPC type:
  Safety signal
• Human ATC codes:
  L04AA29
• Dissemination date:
  06/07/2021